GEHC (GEHC) Stock Analysis 2026

Healthcare
$71.72
as of 2026-08-28

BriMind AI Score

Proprietary
31
Weak
Price CAGR
6.3%
1Y Return
-0.5%
Analyst Upside
+10.3%
Rev Growth
5.8%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$76.86+7.2% potential
Bear Case
$57.51
Bull Case
$107.60
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

GEHC Revenue & Profitability Breakdown

This chart shows how GEHC's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$21.27B
Cost of Revenue
-$12.86B
Gross Profit
$8.41B39.5% margin
Operating Expenses
-$5.22B
Operating Income
$3.18B15.0% margin
Tax & Other
-$1.20B
Net Income
$1.98B9.3% margin
Gross Margin
39.5%
Operating Margin
15.0%
Net Margin
9.3%

Key Financial Metrics

GEHC trades at a trailing P/E of 17.24x, generates $1.57B in free cash flow, runs a debt/equity ratio of 93.97, and converts shareholder equity into profit at a 19.4% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$33.80B
P/E (Trailing)
17.24
P/E (Forward)
13.83
Revenue
$21.27B
Revenue Growth
5.8%
Earnings Growth
16.8%
Gross Margin
39.5%
Operating Margin
15.0%
Net Margin
9.3%
Return on Equity
19.4%
Return on Assets
5.1%
Free Cash Flow
$1.57B
Debt / Equity
93.97
Current Ratio
1.26
Quick Ratio
0.83
Beta
0.82
Dividend Yield
0.2%
Payout Ratio
3.2%
Book Value / Share
$24.30

GEHC Valuation Context

17.2xTrailing P/E

GEHC trades at 17.2x, which is 46% below the Healthcare median of 31.7x.

Sector median computed live across 57 Healthcare companies in our coverage universe with a positive trailing P/E. Forward P/E: 13.8x.

Wall Street Analyst Consensus

Wall Street analysts covering GEHC currently haven't converged on a clear consensus rating, with a mean 12-month price target of $82.50 (+15.0% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$82.50+15.0% upside

Compare GEHC with Peers

GEHC vs MDTGE HealthCare vs Medtronic — Imaging Giant vs Diversifi

Unlock the Full GEHC Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis